Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 540 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Glucagon-like peptide-1 analogues: An overview

Gupta Vishal

Year : 2013| Volume: 17| Issue : 3 | Page no: 413-421

   This article has been cited by
1 Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control
A. Dagbasi,A. M. Lett,K. Murphy,G. Frost
Proceedings of the Nutrition Society. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
2 Apigenin modulates hippocampal CREB-BDNF signaling in high fat, high fructose diet-fed rats
Jagan Kalivarathan,Kalpana Kalaivanan,Sathiya Priya Chandrasekaran,Dipti Nanda,Vidhya Ramachandran,Anuradha Carani Venkatraman
Journal of Functional Foods. 2020; 68: 103898
[Pubmed]  [Google Scholar] [DOI]
3 The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation
Mochao Xiao,Daifeng Lu,Jiali Tian,Yang Yu,Qin Zhang,Lili Zhang,Dong Chang
RSC Advances. 2020; 10(17): 10245
[Pubmed]  [Google Scholar] [DOI]
4 Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced
Rona Zhou,Karsten Duncan,Julio Lopez,Kjersti Rich,Arthur Swislocki
Metabolic Syndrome and Related Disorders. 2020;
[Pubmed]  [Google Scholar] [DOI]
5 Recent advances in understanding the role of glucagon-like peptide 1
Josh Reed,Stephen Bain,Venkateswarlu Kanamarlapudi
F1000Research. 2020; 9: 239
[Pubmed]  [Google Scholar] [DOI]
6 Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation
Chen Li,Shijie Dai,Aijie Cao,Zhifang Zhou,Zhimeng Wu
Journal of Carbohydrate Chemistry. 2019; 38(3): 167
[Pubmed]  [Google Scholar] [DOI]
7 Lead Optimization Resources in Drug Discovery for Diabetes
Pragya Tiwari,Ashish Katyal,Mohd F. Khan,Ghulam Md. Ashraf,Khurshid Ahmad
Endocrine, Metabolic & Immune Disorders - Drug Targets. 2019; 19(6): 754
[Pubmed]  [Google Scholar] [DOI]
8 Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Ajay Sood,Arthur Swislocki
Metabolic Syndrome and Related Disorders. 2019;
[Pubmed]  [Google Scholar] [DOI]
9 An overview on small molecule-induced differentiation of mesenchymal stem cells into beta cells for diabetic therapy
Nimshitha Pavathuparambil Abdul Manaph,Kisha N. Sivanathan,Jodie Nitschke,Xin-Fu Zhou,Patrick T. Coates,Christopher John Drogemuller
Stem Cell Research & Therapy. 2019; 10(1)
[Pubmed]  [Google Scholar] [DOI]
10 Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Seyed Ebrahim Alavi,Peter J. Cabot,Peter M. Moyle
Molecular Pharmaceutics. 2019;
[Pubmed]  [Google Scholar] [DOI]
11 The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jie Wang,Xinye Jin,Ping An,Songyan Yu,Yiming Mu
Journal of Diabetes Research. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
12 Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
Ruba Ismail,Alexandra Bocsik,Gábor Katona,Ilona Gróf,Mária A. Deli,Ildikó Csóka
Pharmaceutics. 2019; 11(11): 599
[Pubmed]  [Google Scholar] [DOI]
13 Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide
Angélique Gajahi Soudahome,Aurélie Catan,Pierre Giraud,Sandrine Assouan Kouao,Alexis Guerin-Dubourg,Xavier Debussche,Nathalie Le Moullec,Emmanuel Bourdon,Susana B. Bravo,Beatriz Paradela-Dobarro,Ezequiel Álvarez,Olivier Meilhac,Philippe Rondeau,Joël Couprie
Journal of Biological Chemistry. 2018; 293(13): 4778
[Pubmed]  [Google Scholar] [DOI]
14 A capillary zone electrophoresis method to investigate the oligomerization of the human Islet Amyloid Polypeptide involved in Type 2 Diabetes
Corentin Berardet,Julia Kaffy,Sandrine Ongeri,Myriam Taverna
Journal of Chromatography A. 2018;
[Pubmed]  [Google Scholar] [DOI]
15 Novel technique of insulin loading into porous carriers for oral delivery
Sarah Y. Eilleia,Mahmoud E. Soliman,Samar Mansour,Ahmed. S. Geneidi
Asian Journal of Pharmaceutical Sciences. 2018;
[Pubmed]  [Google Scholar] [DOI]
16 GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito,Otávio Berwanger,Luiz Sérgio F. de Carvalho,José Francisco Kerr Saraiva
Cardiovascular Diabetology. 2018; 17(1)
[Pubmed]  [Google Scholar] [DOI]
17 Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy
Risa Takayanagi,Takumi Uchida,Koji Kimura,Yasuhiko Yamada
Biological and Pharmaceutical Bulletin. 2018; 41(2): 153
[Pubmed]  [Google Scholar] [DOI]
18 Novel pharmacotherapy for burn wounds: what are the advancements
Michael R. Hamblin
Expert Opinion on Pharmacotherapy. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
19 A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera,Ana Cebrián-Cuenca,Fernando Álvarez-Guisasola,Fernando Gomez-Peralta,Jesús Reviriego
Diabetes Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
20 Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists
Khyati Girdhar,Budheswar Dehury,Mahender Kumar Singh,Vineeth P. Daniel,Abhinav Choubey,Surbhi Dogra,Sunil Kumar,Prosenjit Mondal
Journal of Biomolecular Structure and Dynamics. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
21 Antidiabetic therapies and male reproductive function: where do we stand?
R S Tavares,S Escada-Rebelo,A F Silva,M I Sousa,J Ramalho-Santos,S Amaral
Reproduction. 2018; 155(1): R13
[Pubmed]  [Google Scholar] [DOI]
22 Gold nanoparticles as an efficient drug delivery system for GLP-1 peptides
Magdalena Pérez-Ortiz,Claudio Zapata-Urzúa,Gerardo A. Acosta,Alejandro Álvarez-Lueje,Fernando Albericio,Marcelo J. Kogan
Colloids and Surfaces B: Biointerfaces. 2017; 158: 25
[Pubmed]  [Google Scholar] [DOI]
23 Lixisenatide as add-on treatment among patients with different ß-cell function levels as assessed by HOMA-ß index
Riccardo C. Bonadonna,Lawrence Blonde,Mikhail Antsiferov,Rachele Berria,Pierre Gourdy,Mensud Hatunic,Viswanathan Mohan,Michael Horowitz
Diabetes/Metabolism Research and Reviews. 2017; : e2897
[Pubmed]  [Google Scholar] [DOI]
24 Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee,Dong Yun Lee
Annals of Pediatric Endocrinology & Metabolism. 2017; 22(1): 15
[Pubmed]  [Google Scholar] [DOI]
25 The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy. 2017;
[Pubmed]  [Google Scholar] [DOI]
26 Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core
Kellie D. Nance,Emily L. Days,C. David Weaver,Anastasia Coldren,Tiffany D. Farmer,Hyekyung P. Cho,Colleen M. Niswender,Anna L. Blobaum,Kevin D. Niswender,Craig W. Lindsley
Journal of Medicinal Chemistry. 2017;
[Pubmed]  [Google Scholar] [DOI]
27 Peptibodies: An elegant solution for a long-standing problem
Marco Cavaco,Miguel A. R. B. Castanho,Vera Neves
Biopolymers. 2017; : e23095
[Pubmed]  [Google Scholar] [DOI]
28 A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Sheena Kayaniyil,Greta Lozano-Ortega,Heather A. Bennett,Kristina Johnsson,Alka Shaunik,Susan Grandy,Bernt Kartman
Diabetes Therapy. 2016;
[Pubmed]  [Google Scholar] [DOI]
29 Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Markolf Hanefeld,Denis Raccah,Louis Monnier
Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
30 Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions
Amit Lakhanpal,Ernest Brahn
Clinical Rheumatology. 2016; 35(12): 2869
[Pubmed]  [Google Scholar] [DOI]
31 Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé ?
J.-F. Blicklé
Médecine des Maladies Métaboliques. 2016; 10(6): 574
[Pubmed]  [Google Scholar] [DOI]
32 Albiglutide: a unique GLP-1 receptor agonist
Marc S. Rendell
Expert Opinion on Biological Therapy. 2016; 16(12): 1557
[Pubmed]  [Google Scholar] [DOI]
33 Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice
L M McShane,N Irwin,D O’Flynn,Z J Franklin,C M Hewage,F P M O’Harte
Journal of Endocrinology. 2016; 229(3): 319
[Pubmed]  [Google Scholar] [DOI]
34 Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation
Harika Meduru,Yeng-Tseng Wang,Jeffrey Tsai,Yu-Ching Chen
International Journal of Molecular Sciences. 2016; 17(6): 920
[Pubmed]  [Google Scholar] [DOI]
35 Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+–XO–ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways
Ying Zhang,Hao Zhou,Wenbo Wu,Chen Shi,Shunying Hu,Tong Yin,Qiang Ma,Tianwen Han,Yingqian Zhang,Feng Tian,Yundai Chen
Free Radical Biology and Medicine. 2016; 95: 278
[Pubmed]  [Google Scholar] [DOI]
36 Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
Ali A Rizvi,Angelo Maria Patti,Rosaria Vincenza Giglio,Dragana Nikolic,Antonella Amato,Noor Al-Busaidi,Khalid Al-Rasadi,Maurizio Soresi,Maciej Banach,Giuseppe Montalto,Manfredi Rizzo
Expert Opinion on Biological Therapy. 2015; 15(10): 1391
[Pubmed]  [Google Scholar] [DOI]
37 Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes
Nigel Irwin,Steven Patterson,Martin de Kort,R. Charlotte Moffett,Jeffry A. J. Wisse,Wim H. A. Dokter,Ebo S. Bos,André M. M. Miltenburg,Peter R. Flatt
ChemMedChem. 2015; 10(8): 1424
[Pubmed]  [Google Scholar] [DOI]
38 Incretin-based therapies for obesity treatment
Aline Haas de Mello,Morgana Prá,Larissa Colonetti Cardoso,Rosiane de Bona Schraiber,Gislaine Tezza Rezin
Metabolism. 2015; 64(9): 967
[Pubmed]  [Google Scholar] [DOI]
39 Enhanced survival of human mesenchymal stem cells following co-delivery with glucagon-like peptide-1 analogue in fibrin gel
Hyerim Jin,Woo Jung Lee,Soongdong Lee,TacGhee Yi,Sun Uk Song,Gayong Shim,Yu-Kyoung Oh
Journal of Pharmaceutical Investigation. 2014;
[Pubmed]  [Google Scholar] [DOI]
40 Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography–tandem mass spectrometry
Xiaoyan Zhu,Jingjing Liu,Jie Wu,Rongyue Cao,Taiming Li
Journal of Chromatography B. 2014; 967: 50
[Pubmed]  [Google Scholar] [DOI]


Read this article